Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia

Schizophrenia Bulletin

Volumn 30, Issue 2, 2004, Pages 241-253

  Das, Mrigendra ^b,c   Kumari, Veena ^b   Soni, William ^b   Ettinger, Ulrich ^b   Binneman, Brendan ^b   Hughes, Catherine ^b   Mehrotra, Ravi ^b   Sharma, Tonmoy ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c BROADMOOR HOSPITAL   (United Kingdom)

Author keywords

Atypical antipsychotics; Cognition; Neurological soft signs; Psychopathology; Schizophrenia; Treatment

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INTELLIGENCE QUOTIENT; MALE; MEMORY; MENTAL DISEASE; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 3042532178     PISSN: 05867614     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.schbul.a007075     Document Type: Article

References (46)

1. American Psychiatric Association. DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: APA, 1994.
2. Andreasen, N.C.; Arndt, S.; Swayze, V.I.; Cizadlo, T.; Flaum, M.; O'Leary, D.; Ehrhardt J.C.; and Yuh, W.T.C. Thalamic abnormalities in schizophrenia visualised through magnetic resonance image averaging. Science, 266:294-298, 1994.
3. Arango, C.; Bartko, J.J.; Gold, J.M.; and Buchanan, R.W. Prediction of neuropsychological performance by neurological signs in schizophrenia. American Journal of Psychiatry, 156:1349-1357, 1999.
4. Bazire, S. Psychotropic Drug Directory. Wiltshire, U.K.: Mark Allen Publishing, 1995.
5. Benton, A.L.; Hamsher, K.; Varney, N.R.; and Spreen, O. Contributions to Neuropsychological Assessment. New York, NY: Oxford University Press, 1983.
6. Boks, M.P.M.; Russo, S.; Knegtering, R.; and van den Bosch, R.J. The specificity of neurological signs in schizophrenia: A review. Schizophrenia Research, 43:109-116, 2000.
7. Brandt, J. The Hopkins selective memory test: Development of a new memory test with six equivalent forms. Clinical Neuropsychology, 5:125-142, 1991.
8. Buchanan, R.W., and Heinrichs, D.W. The Neurological Evaluation Scale (NES): A structured instrument for the assessment of neurological signs in schizophrenia. Psychiatry Research, 27:335-350, 1989.
9. Buchanan, R.W.; Kirkpatrick, B.; Heinrichs, D.W.; and Carpenter, W.T., Jr. Clinical correlates of the deficit syndrome of schizophrenia. American Journal of Psychiatry, 147:290-294, 1990.
10. Buchanan, R.W.; Koeppl, P.; and Brier, A. Stability of neurological signs with clozapine treatment. Biological Psychiatry, 36:198-200, 1994.
11. Conners, C.K. Conners' Continuous Performance Test Computer Program 3.0: User's Manual. Toronto, Canada: Multi-Health Systems, 1995.
12. Convit, A.; Volavka, J.; Czobor, P.; de Asis, J.; and Evangelista, C. Effect of subtle neurological dysfunction in response to haloperidol treatment in schizophrenia. American Journal of Psychiatry, 151:41-56, 1994.
13. Fish, B. Neurobiological antecedents of schizophrenia in children: Evidence for an inherited, congenital neurointegrative defect. Archives of General Psychiatry, 34:1297-1313, 1977.
14. Flashman, L.A.; Flaum, M.; Gupta, S.; and Andreasen, N.C. Soft signs and neuropsychological performance in schizophrenia. American Journal of Psychiatry, 153:526-532, 1996.
15. Griffiths, T.D.; Sigmundsson, T.; Takei, N.; Rowe, D.; and Murray, R.M. Neurological abnormalities in familial and sporadic schizophrenia. Brain, 121:191-203, 1998.
16. Gupta, S.; Andreasen, N.C.; Arndt, S.; Flaum, M.; Schultz, M.D.; Hubbard, W.C.; and Smith, M. Neurological soft signs in neuroleptic-naive and neuroleptic-treated schizophrenic patients and in normal comparison subjects. American Journal of Psychiatry, 152:191-196, 1995.
17. Harvey, P.D., and Keefe, R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry, 158:176-184, 2001.
18. Heaton, R.K. Wisconsin Card Sorting Test: Computer Version-2 Research Edition. Odessa, FL: Psychological Assessment Resources, 1993.
19. Heinrichs, D.W., and Buchanan, R.W. Significance and meaning of neurological signs in schizophrenia. American Journal of Psychiatry, 145:11-18, 1988.
20. Honey, G.D.; Bullmore, E.T.; Soni, W.; Varatheesan, M.; Williams, S.C.R.; and Sharma, T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 96:13432-13437, 1999.
21. Johnstone, E.C.; Macmillan, J.F.; Frith, C.D.; Benn, D.K.; and Crow, T.J. Further investigation of the predictors of outcome following schizophrenic episodes. British Journal of Psychiatry, 157:182-189, 1990.
22. Kay, S.R.; Fiszbein, A.; and Opler, L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13(2):261-276, 1987.
23. Keefe, R.S.E.; Silva, S.G.; Perkins, D.O.; and Lieberman, J.A. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. Schizophrenia Bulletin, 25(2):201-222, 1999.
24. King, D.J.; Wilson, A.; Cooper, S.J.; and Waddington, J.L. The clinical correlates of neurological soft signs in chronic schizophrenia. British Journal of Psychiatry, 158:770-775, 1991.
25. Kolakowska, T.; Williams, A.O.; Jambor, K.; and Ardern, M. Schizophrenia with a good and poor outcome: III: Neurological soft signs, cognitive impairment and their clinical significance. British Journal of Psychiatry, 146:348-357, 1985.
26. Kumari, V.; Soni, W.; and Sharma, T. Normalization of information processing deficits in schizophrenia with clozapine. American Journal of Psychiatry, 156:1046-1051, 1999.
27. Lezak, M.L. Neuropsychological Assessment. Oxford, U.K.: Oxford University Press, 1983.
28. Meltzer, H.Y., and McGurk, S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin, 25(2):233-255, 1999.
29. Merriam, A.E.; Kay, S.R.; Opler, L.A.; Kushner, S.F.; and van Praag, V.M. Neurological soft signs and positive-negative dimension in schizophrenia. Biological Psychiatry, 28:181-192, 1990.
30. Miceli, G.; Caltagirone, C.; Gianotti, G.; Masullo, C.; and Silveri, M.C. Neuropsychological correlates of localised cerebral lesions in nonaphasic brain-damaged patients. Journal of Clinical Neuropsychology, 3:53-63, 1981.
31. Mohr, F.; Hubmann, W.; Cohen, R.; Bender, W.; Haslacher, C.; Honicke, S.; Schlenker, R.; Wahlheim, C.; and Werther, P. Neurological soft signs in schizophrenia: Assessment and correlates. European Archives of Psychiatry and Clinical Neuroscience, 246:240-248, 1996.
32. Morris, R.G. The Computerised Trail Making Test. London, U.K.: Institute of Psychiatry, 1995.
33. Nelson, H.E. National Adult Reading Test (NART): Test Manual. Windsor, U.K.: NFER-Nelson Publishing Company, 1982.
34. Oldfield, R.C. The assessment and analysis of handedness: The Edinburgh Inventory. Neuropsychologia, 9:97-114, 1971.
35. Parnas, J.; Schulsinger, F.; Teasdale, T.W.; Schulsinger, H.; Feldman, P.M.; and Mednick, S.A. Perinatal complications and clinical outcome within the schizophrenia spectrum, British Journal of Psychiatry, 140:416-420, 1982.
36. Quitkin, F.; Rifkin, A.; and Klein, D.F. Neurological soft signs in schizophrenia and character disorders: Organicity in schizophrenia with premorbid asociality and emotionally unstable character disorders. Archives of General Psychiatry, 33:845-853, 1976.
37. Sharma, T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. British Journal of Psychiatry, 174(Suppl 38):44-51, 1999.
38. Smith, R.; Hussain, M.I.; Chowdhury, S.A.; and Stearns, A. Stability of neurological soft signs in chronically hospitalized schizophrenic patients. Journal of Neuropsychiatry and Clinical Neurosciences, 11:91-96, 1999a.
39. Smith, R., and Kadewari, R.P. Neurological soft signs and response to risperidone in chronic schizophrenia. Biological Psychiatry, 40:1056-1059, 1996.
40. Smith, R.C.; Kadewari, R.P.; Rosenberger, J.R.; and Bhattacharyya, A. Nonresponding schizophrenia: Differentiation by neurological soft signs and neuropsychological tests. Schizophrenia Bulletin, 25(4):813-825, 1999b.
41. Vaid, G.; Smith, R.C.; Rosenberger, J.; and Alter, I. Neurological and neuropsychological tests in schizophrenics. [Abstract]. Biological Psychiatry, 33(Suppl 6A):92, 1993.
42. Wechsler, D. Wechsler Memory Scale. New York, NY: The Psychological Corporation, 1945.
43. Wechsler, D. Wechsler Adult Intelligence Scale-Revised. New York, NY: The Psychological Corporation, 1981.
44. Weiser, M.; Shneider-Beeri, M.; Nakash, N.; Brill, N.; Bawnik, O.; Reiss, S.; Hocherman, S.; and Davidson, M. Improvement in cognition associated with novel antipsychotic drugs: A direct drug effect or reduction of EPS? Schizophrenia Research, 46:81-89, 2000.
45. Wong, A.; Voruganti, L.; Heslegrave, R.J.; and Awad, A.G. Neuroognitive deficits and neurological signs in schizophrenia. Schizophrenia Research, 23:139-146, 1997.
46. Yee, C.M.; Nuechterlein, K.H.; Morris, S.E.; and White, P.M. P50 suppression in recent-onset schizophrenia: Clinical correlates and risperidone effects. Journal of Abnormal Psychology, 107:691-698, 1998.